

Ryuichi Mizuno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3117032/publications.pdf>

Version: 2024-02-01

47
papers

980
citations

471509

17
h-index

434195

31
g-index

48
all docs

48
docs citations

48
times ranked

1841
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal cancer cells lacking hypoxia inducible factor (HIF)-1 α expression maintain vascular endothelial growth factor expression through HIF-2 α . <i>Carcinogenesis</i> , 2006, 28, 529-536.	2.8	145
2	Increased nuclear factor- κ B activation is related to the tumor development of renal cell carcinoma. <i>Carcinogenesis</i> , 2003, 24, 377-384.	2.8	111
3	Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis. <i>Laboratory Investigation</i> , 2011, 91, 1443-1458.	3.7	101
4	Expression of $\text{TNF-}\alpha$ and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. <i>International Journal of Cancer</i> , 2015, 136, 1504-1514.	5.1	99
5	Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 1820-1828.	3.9	45
6	Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma. <i>BJU International</i> , 2016, 118, 598-603.	2.5	42
7	Recent advances in renal cell carcinoma from a pathological point of view. <i>Pathology International</i> , 2016, 66, 481-490.	1.3	40
8	Increased activation of CCAAT/enhancer binding protein-beta correlates with the invasiveness of renal cell carcinoma. <i>Clinical Cancer Research</i> , 2003, 9, 1021-7.	7.0	37
9	Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer. <i>BMC Cancer</i> , 2015, 15, 324.	2.6	35
10	β -isobromoamide, an extract from <i>Lycyngbya</i> species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells. <i>Cancer Medicine</i> , 2013, 2, 32-39.	2.8	25
11	Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model Dr. Mizuno reports grants from The Japan Agency for Medical Research and Development (AMED), personal fees from Pfizer, grants and personal fees from Novartis, during the conduct of the study. Dr. Mikami reports grants from The Japan Agency for Medical Research and Development (AMED) during the con. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 39.e19-39.e28.	1.6	24
12	Maximum tumor diameter is a simple and valuable index associated with the local extent of disease in clinically localized prostate cancer. <i>International Journal of Urology</i> , 2006, 13, 951-955.	1.0	23
13	Patterns of Interstitial Lung Disease During Everolimus Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 442-446.	1.3	23
14	External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study. <i>European Urology Focus</i> , 2016, 2, 303-309.	3.1	21
15	Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy. <i>Medical Oncology</i> , 2017, 34, 47.	2.5	20
16	Comparison of continence outcomes of early catheter removal on postoperative day 2 and 4 after laparoscopic radical prostatectomy: a randomized controlled trial. <i>BMC Urology</i> , 2015, 15, 77.	1.4	19
17	Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e927-e933.	1.9	19
18	Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma. <i>Cancer Science</i> , 2017, 108, 1858-1863.	3.9	18

#	ARTICLE	IF	CITATIONS
19	Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients. <i>Laboratory Investigation</i> , 2017, 97, 854-862.	3.7	17
20	Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 154-164.	2.2	16
21	Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e575-e583.	1.9	10
22	Classification of solid renal tumor with oncocytic/eosinophilic cytoplasm: is hybrid oncocytic/chromophobe renal tumor a subtype of oncocytoma, chromophobe renal cell carcinoma, or a distinct tumor entity?. <i>Annals of Translational Medicine</i> , 2019, 7, S350-S350.	1.7	8
23	Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. <i>International Journal of Oncology</i> , 2006, 28, 841-6.	3.3	8
24	Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma. <i>CEN Case Reports</i> , 2021, 10, 281-286.	0.9	7
25	Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. <i>Medical Oncology</i> , 2014, 31, 45.	2.5	6
26	Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1069-1074.	2.2	6
27	Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy. <i>World Journal of Urology</i> , 2020, 38, 1749-1756.	2.2	6
28	Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 287-295.	1.3	6
29	Effects of transurethral resection under general anesthesia on tumor recurrence in non-muscle invasive bladder cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2094-2103.	2.2	6
30	Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma. <i>Pathology International</i> , 2020, 70, 712-723.	1.3	5
31	Diagnostic value of texture analysis of apparent diffusion coefficient maps for differentiating fat-poor angiomyolipoma from non-clear-cell renal cell carcinoma. <i>European Journal of Radiology</i> , 2021, 143, 109895.	2.6	5
32	Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 293.e17-293.e25.	1.6	4
33	Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 69-76.	1.3	4
34	Immunoglobulin G4-Related Disease Arising from the Bladder Wall. <i>Urologia Internationalis</i> , 2019, 103, 488-490.	1.3	3
35	Renal hemorrhage caused by acquired inhibitors to coagulation factors VIII and V in a hemodialysis patient. <i>CEN Case Reports</i> , 2016, 5, 223-226.	0.9	2
36	Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 1170-1174.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy. Japanese Journal of Clinical Oncology, 2019, 49, 780-785.	1.3	2
38	On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma. International Journal of Clinical Oncology, 2021, 26, 1500-1505.	2.2	2
39	Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer. Japanese Journal of Clinical Oncology, 2022, 52, 388-396.	1.3	2
40	Exacerbation of diabetic nephropathy mimicking thrombotic microangiopathy during sunitinib treatment for metastatic renal cell carcinoma. International Cancer Conference Journal, 2012, 1, 183-189.	0.5	1
41	Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor. International Journal of Urology, 2014, 21, 740-740.	1.0	1
42	A case of paraneoplastic liver dysfunction with elevated serum interleukin-6 in clinically localized renal cell carcinoma. International Cancer Conference Journal, 2016, 5, 66-67.	0.5	1
43	Idiopathic hemocele in a patient receiving peritoneal dialysis. Clinical and Experimental Nephrology, 2017, 21, 350-351.	1.6	1
44	Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 61-69.	0.4	1
45	Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery. Japanese Journal of Clinical Oncology, 2021, 51, 984-991.	1.3	1
46	Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 744-752.	2.2	0
47	Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1722-1728.	2.2	0